Between the two, semaglutide and tirzepatide consistently lead the clinical data, and the right choice usually depends on BMI, metabolic history, and how the body responds to the starting dose
As for clinical outcomes, in the T2DM group, there was a significant reduction in HbA1c (decreased by 1.01% to 1.02%, placebo-adjusted) and a clinically meaningful decrease in body weight of 3.26% to 3.51% after 12 weeks of treatment
When weight comes off too quickly, your body doesnt just burn fatit breaks down muscle too
K., Dukle, A., & Nathanael, A
Details about any diagnosed comorbidities and how they relate to your weight